In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPC/NeoTherapeutics: Winners and Losers

Executive Summary

Struggling for cash after its lead compound failed earlier this year, NeoTherapeutics had little choice but to out-license its Phase II cancer compound, satraplatin. Germany's GPC Biotech was ready to strike. Unlike its compatriots, GPC has the cash-and newly hired management experience-to fund and oversee the rest of satraplatin's development.
Advertisement

Related Content

Biotechs on the Brink Choose Last-Minute Deals, Not Liquidation
GPC: A Model for the Rest of Us
GPC: A Model for the Rest of Us
Germany's Biotech Bust

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel